The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Frontline treatment of transplant-ineligible MM: a changing landscape
The majority of multiple myeloma (MM) patients are not transplant eligible – although the definition of transplant eligibility is now changing. Here, Noopur Raje, MD, from Massachusetts General Hospital, Boston, MA, gives her thoughts on the best frontline therapy for this patient group. Dr Raje highlights data from the ALCYONE (NCT02195479), SWOG (NCT01903811) and RVD Lite (NCT01782963) trials, and emphasizes the importance of achieving deep remissions even in elderly patients. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
